LB Pharmaceuticals Inc LBRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.97M | 7.46M | 4.99M | 2.83M | 2.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.02M | 22.00M | 12.97M | 5.25M | 4.86M |
| Operating Income | -52.02M | -22.00M | -12.97M | -5.25M | -4.86M |
| Income Before Tax | -51.60M | -19.05M | -11.47M | -3.56M | -4.87M |
| Income Tax Expenses | -- | -- | 1.00K | -- | -- |
| Earnings from Continuing Operations | -51.60M | -19.05M | -11.47M | -3.56M | -4.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.60M | -19.05M | -11.47M | -3.56M | -4.87M |
| EBIT | -52.02M | -22.00M | -12.97M | -5.25M | -4.86M |
| EBITDA | -51.92M | -21.92M | -12.89M | -5.17M | -4.78M |
| EPS Basic | -1.71 | -0.67 | -0.45 | -0.61 | -13.58 |
| Normalized Basic EPS | -1.03 | -0.42 | -0.26 | -0.38 | -8.48 |
| EPS Diluted | -1.71 | -0.67 | -0.45 | -0.61 | -13.58 |
| Normalized Diluted EPS | -1.03 | -0.42 | -0.26 | -0.38 | -8.48 |
| Average Basic Shares Outstanding | 30.14M | 28.24M | 25.41M | 5.81M | 358.80K |
| Average Diluted Shares Outstanding | 30.14M | 28.24M | 25.41M | 5.81M | 358.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |